Printed From:

SOLIQUA 100/33 works 5 ways to help deliver blood control sugar and lower your A1 illustration

SOLIQUA 100/33 works 5 ways in your body

SOLIQUA 100/33 works 5 ways to deliver blood sugar control and help lower A1c.

  1. Bloodstream Helps reduce sugar buildup in your bloodstream
  2. Stomach Slows down the process by which sugar enters your bloodstream after eating
  3. Liver Helps slow down the processes by which the liver releases sugar into the bloodstream
  4. Pancreas Helps your pancreas release more insulin to help maintain lower blood sugar levels
  5. Muscles Helps muscles store glucose that your body doesn’t need right away so it can be used for energy later

Ask your doctor if SOLIQUA 100/33 is right for you

SOLIQUA 100/33 is proven to lower A1c to below 7%*graph

SOLIQUA 100/33 is proven to lower A1c below 7%

In a clinical study, more than half (55%) of patients using SOLIQUA 100/33 lowered their A1c below 7%, while 30% of patients using Lantus® reached an A1c below 7%. On average, A1c was reduced from a starting point of 8.1% to 6.9% in patients taking SOLIQUA 100/33. In patients taking Lantus®, A1c was reduced from 8.1% to 7.5%.

See how the clinical study worked below.

Almost twice the A1c reduction of
Lantus® alone

2X Almost twice the A1c REDUCTION

In the same clinical study, patients using SOLIQUA 100/33 achieved almost twice the A1c reduction than patients who were using Lantus® (1.1% reduction vs. 0.6% reduction).

How the clinical study worked:

Who participated:

  • Adults with type 2 diabetes currently using long-acting insulin, but who were not at their A1c goal were considered. (They had an average A1c of 8.5% and a fasting blood sugar ≤ 180 mg/dL.)

What happened:

  • Selected patients were given Lantus® (insulin glargine 100 Units/mL) for 6 weeks. (1,018 patients)
  • After 6 weeks, patients with an A1c of 8.1% and fasting blood sugar of ≤ 140 mg/mL continued in the trial. (736 patients)
  • For the next 30 weeks about half of those patients continued on Lantus® and the other half received SOLIQUA 100/33 (a combination of Lantus®, a long-acting insulin, and Adlyxin™, a non-insulin diabetes medicine).

What the study compared:

  • The study was designed to show how adding a non-insulin diabetes medicine to Lantus®, a long-acting insulin, in a single injection improves blood sugar control.
  • Patients in each group received a dose no greater than 60 units of insulin daily. Only the SOLIQUA 100/33 group received the medicine that combines both Lantus® and a non-insulin diabetes medicine. The study showed how combining a non-insulin diabetes medicine with Lantus® could help to lower blood sugar even further.

What you should know about the possible side effects of SOLIQUA 100/33

The most common side effects of SOLIQUA 100/33 may include low blood sugar (hypoglycemia), nausea, headache, stuffy or runny nose and sore throat, allergic reactions, diarrhea, and upper respiratory tract infection.

Nausea and diarrhea usually happen more often when you start using SOLIQUA 100/33.

Individual results may vary. Your doctor may prescribe other insulin doses. The differences between Lantus® and SOLIQUA 100/33 seen in the trial may not reflect your results.

SOLIQUA 100/33 delivers blood sugar control through the day and night clock icon

Helps manage blood sugar all day and night

SOLIQUA 100/33 delivers blood sugar control throughout the day and night.